First Solar, Inc. (NASDAQ:FSLR): Current price $39.93
First Solar has acquired General Electric’s global cadmium telluride solar intellectual property portfolio in return for 1.75 million shares of the buyer, which it will retain for at least three years. However, Deutsche Bank analysts were a bit skeptical in regards to the transaction, contending that it “raises some questions about timing/intent, especially considering the fact that the technology portfolio is unlikely to impact efficiency until 2017 timeframe.” First Solar shares are down more than 13 percent Wednesday on heavy trading.
Opexa Therapeutics, Inc. (NASDAQ:OPXA): Current price $2.87
On Wednesday, Opexa commemorated World MS Day with a renewed commitment to the multiple sclerosis community. The biotech firm will sponsor a booth and present baseline data from its Immune Monitoring Program in a poster session at the 2013 Annual Meeting of the Consortium of Multiple Sclerosis Centers & the Fifth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis May 29 through June 1 in Orlando. Since May 2009, the Multiple Sclerosis International Federation has organized a World Multiple Sclerosis Day, and this year it is being celebrated again on May 29. Opexa is a biotechnology company developing a patient specific T-cell immunotherapy for multiple sclerosis.
SandRidge Energy Inc. (NYSE:SD): Current price $5.35
SandRidge posted its second-quarter 2013 results before the open Wednesday morning. The independent oil and gas firm reported adjusted diluted earnings per share of 8 cents on revenues of $512.99 million compared year-over-year top 7 cents on revenues of $478.43 million. The current results also compare to the Thomson Reuters consensus estimates for a net loss of 3 cents per share and $424.16 million in revenues. On a GAAP basis, SandRidge posted a loss of 7 percent per share.